Novartis to Partner with Amgen For Development of Neuroscience Treatments

Swiss drug maker Novartis said today that it would co-operate with California based biotech giant Amgen for the development and sell neuroscience treatments for illnesses and ailments like Alzheimer’s disease and migraine headaches. In a statement, the company said that as part of the deal, Amgen would make initial payments and cover some research and development costs at the start with regard to the BACE inhibitor program for treatment of Alzheimer’s. The company added that this would be followed by a 50-50 cost and profit sharing arrangement. The development is being seen as a huge positive by industry experts from both the companies. As for migraine, it was reported that Novartis will fund some research and development expenses for an agreed period and pay Amgen double digit royalties on sales.…


Link to Full Article: Novartis to Partner with Amgen For Development of Neuroscience Treatments